onlinecasinobonus| Qingdao Baiyang Pharmaceutical once again passed FDA on-site inspection with zero defects

May 17onlinecasinobonusQingdao Baiyang Pharmaceutical Co., Ltd.(hereinafter referred to as "Qingdao Baiyang Pharmaceutical"), a subsidiary of Shanghai Baiyang Pharmaceutical Co., Ltd., received an official notice from the U.S. Food and Drug Administration (FDA) that Qingdao Baiyang Pharmaceutical passed the FDA with NAI (No Action Indicated, No Rectification Required) zero "483" defectsonlinecasinobonusOn-site inspection of cGMP (Current Good Manufacturing Practice). This is the first time that Qingdao Baiyang Pharmaceutical passed the FDA inspection with zero "483" defects after passing the "zero defect" inspection in 2016.

Tags：

Article Copyright Statement: Unless otherwise specified, all articles are jiliasia16 com original. Reproduction or reproduction should be in the form of hyperlinks and indicate the source.